Global Otitis Media Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Otitis Media treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Lee's Pharmaceutical Holdings Ltd, Madam Therapeutics BV, MerLion Pharmaceuticals Pte Ltd, Novus Therapeutics Inc, Olymvax Biopharmaceuticals Inc and others.
A Significant contribution to the Otitis Media pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Otitis Media pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Otitis Media condition and increased access to investments is encouraging growth of Otitis Media drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Otitis Media drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Otitis Media therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Otitis Media pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Otitis Media. Further, orphan drug status, fast track designation, grants awarded and other special status for Otitis Media pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Otitis Media pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Otitis Media Pipeline candidates-
A Significant contribution to the Otitis Media pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Otitis Media pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Otitis Media condition and increased access to investments is encouraging growth of Otitis Media drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Otitis Media drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Otitis Media therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Otitis Media pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Otitis Media. Further, orphan drug status, fast track designation, grants awarded and other special status for Otitis Media pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Otitis Media pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Otitis Media Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Otitis Media drugs
- Late phase: Phase 3 and in-approval Otitis Media drugs
- Company overview
- Snapshot
- Otitis Media therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Otitis Media- Disease Overview
2.2 Otitis Media- Pipeline Snapshot
2.3 Otitis Media- Pipeline Drugs by Phase
2.4 Otitis Media- Pipeline Drugs by Company
2.5 Otitis Media- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Lee's Pharmaceutical Holdings Ltd Otitis Media Drug Pipeline, H2- 2019
3.2 Madam Therapeutics BV Otitis Media Drug Pipeline, H2- 2019
3.3 MerLion Pharmaceuticals Pte Ltd Otitis Media Drug Pipeline, H2- 2019
3.4 Novus Therapeutics Inc Otitis Media Drug Pipeline, H2- 2019
3.5 Olymvax Biopharmaceuticals Inc Otitis Media Drug Pipeline, H2- 2019
3.6 ProclaRx LLC Otitis Media Drug Pipeline, H2- 2019
3.7 Yuhan Corp Otitis Media Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Otitis Media- Phase 1 Drug Details
4.2 Otitis Media- Phase 1 Drug Overview
4.3 Otitis Media- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Otitis Media- Phase 2 Drug Details
5.2 Otitis Media- Phase 2 Drug Overview
5.3 Otitis Media- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Otitis Media- Phase 3 Drug Details
6.2 Otitis Media- Phase 3 Drug Overview
6.3 Otitis Media- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Otitis Media- Pre-clinical Phase Drug Details
7.2 Otitis Media- Pre-clinical Phase Drug Overview
7.3 Otitis Media- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Otitis Media- Disease Overview
2.2 Otitis Media- Pipeline Snapshot
2.3 Otitis Media- Pipeline Drugs by Phase
2.4 Otitis Media- Pipeline Drugs by Company
2.5 Otitis Media- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Lee's Pharmaceutical Holdings Ltd Otitis Media Drug Pipeline, H2- 2019
3.2 Madam Therapeutics BV Otitis Media Drug Pipeline, H2- 2019
3.3 MerLion Pharmaceuticals Pte Ltd Otitis Media Drug Pipeline, H2- 2019
3.4 Novus Therapeutics Inc Otitis Media Drug Pipeline, H2- 2019
3.5 Olymvax Biopharmaceuticals Inc Otitis Media Drug Pipeline, H2- 2019
3.6 ProclaRx LLC Otitis Media Drug Pipeline, H2- 2019
3.7 Yuhan Corp Otitis Media Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Otitis Media- Phase 1 Drug Details
4.2 Otitis Media- Phase 1 Drug Overview
4.3 Otitis Media- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Otitis Media- Phase 2 Drug Details
5.2 Otitis Media- Phase 2 Drug Overview
5.3 Otitis Media- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Otitis Media- Phase 3 Drug Details
6.2 Otitis Media- Phase 3 Drug Overview
6.3 Otitis Media- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Otitis Media- Pre-clinical Phase Drug Details
7.2 Otitis Media- Pre-clinical Phase Drug Overview
7.3 Otitis Media- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
